Automate Your Wheel Strategy on TMO
With Tiblio's Option Bot, you can configure your own wheel strategy including TMO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TMO
- Rev/Share 114.3175
- Book/Share 133.8677
- PB 3.729
- Debt/Equity 0.6975
- CurrentRatio 1.933
- ROIC 0.0821
- MktCap 188160283480.0
- FreeCF/Share 16.3228
- PFCF 30.496
- PE 28.6078
- Debt/Assets 0.348
- DivYield 0.0033
- ROE 0.1327
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TMO | William Blair | -- | Outperform | -- | -- | Aug. 19, 2025 |
| Downgrade | TMO | HSBC Securities | Buy | Hold | -- | $510 | July 24, 2025 |
| Upgrade | TMO | Scotiabank | Sector Perform | Sector Outperform | -- | $590 | July 11, 2025 |
| Downgrade | TMO | UBS | Buy | Neutral | -- | $460 | July 9, 2025 |
| Upgrade | TMO | Bernstein | Market Perform | Outperform | -- | $630 | Jan. 10, 2025 |
| Initiation | TMO | Scotiabank | -- | Sector Perform | -- | -- | Dec. 23, 2024 |
| Initiation | TMO | Redburn Atlantic | -- | Buy | -- | -- | Oct. 14, 2024 |
| Initiation | TMO | Stephens | -- | Overweight | -- | $680 | Oct. 1, 2024 |
| Initiation | TMO | Wells Fargo | -- | Overweight | -- | $670 | Aug. 28, 2024 |
News
TMO Receives FDA Approval for Oncomine Dx Target Test
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Thermo Fisher secures FDA approval for its Oncomine Dx Target Test to identify NSCLC patients eligible for HERNEXEOS treatment.
Read More
Final Trades: Toast, Transdigm, Thermo Fisher and Amazon
Published: August 13, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Thermo Fisher Q2: Pharma And Biotech Gains Offset By Weak Academic And Gov't Markets
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Positive
I reiterate my Buy rating on Thermo Fisher Scientific Inc., with a fair value estimate of $568 per share, reflecting its undervalued stock price. Q2 FY25 results showed early signs of market recovery, with 2% organic revenue growth and raised full-year revenue and EPS guidance. Pharma and biotech segments are recovering, but academic and government markets face headwinds from U.S. funding uncertainties and policy risks.
Read More
Trade tracker: Bill Baruch buys Thermo Fisher
Published: August 01, 2025 by: CNBC Television
Sentiment: Positive
Bill Baruch, founder and president at Blue Line Capital, joins CNBC's “Halftime Report” to explain why he's buying Thermo Fisher here.
Read More
Thermo Fisher Scientific Showcases Diagnostics Solutions Designed to Meet Evolving Global Healthcare Demands at ADLM 2025
Published: July 28, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, showcases its innovations in improving clinical and diagnostic laboratory efficiency and workflow optimization during the Association for Diagnostics & Laboratory Medicine Conference (ADLM), July 27-31, 2025, in Chicago, Ill. The company debuts two new solutions, LabLink360™* and Thermo Scientific™ MAS™ Max quality controls, designed to support quality control assurance and streamline workflows in clini.
Read More
Thermo Fisher Scientific Stock Jumps on Strong Results, Higher Outlook
Published: July 23, 2025 by: Investopedia
Sentiment: Positive
Thermo Fisher Scientific (TMO) shares took off after the maker of lab equipment and other life sciences products posted better-than-expected results and boosted its guidance, citing operational improvements and lower expected impacts from new tariffs.
Read More
Thermo Fisher shares surge after Q2 beat, boosted by product launches
Published: July 23, 2025 by: Proactive Investors
Sentiment: Positive
Shares of Thermo Fisher Scientific Inc (NYSE:TMO, ETR:TN8) jumped nearly 12% on Wednesday morning after the company reported second-quarter results that topped Wall Street estimates, fueled by strong demand across its life sciences and diagnostics segments. The company posted revenue of $10.86 billion, surpassing analysts' expectations of $10.69 billion and marking a 3% year-over-year increase.
Read More
Thermo Fisher Q2 Earnings & Revenues Beat, Stock Up in Pre-Market
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
TMO tops Q2 estimates as new product launches and solid segment growth fuel revenue gains despite margin pressure.
Read More
Thermo Fisher Scientific Inc. (TMO) Q2 2025 Earnings Call Transcript
Published: July 23, 2025 by: Seeking Alpha
Sentiment: Neutral
Thermo Fisher Scientific Inc. (NYSE:TMO ) Q2 2025 Earnings Conference Call July 23, 2025 8:30 AM ET Company Participants Marc N. Casper - Chairman, President & CEO Rafael Tejada - Vice President of Investor Relations Stephen Williamson - Senior VP & CFO Conference Call Participants Daniel Anthony Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Daniel Gregory Brennan - TD Cowen, Research Division Jack Meehan - Nephron Research LLC Michael Leonidovich Ryskin - BofA Securities, Research Division Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division Tycho W.
Read More
Thermo Fisher (TMO) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Thermo Fisher (TMO) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Thermo Fisher (TMO) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Thermo Fisher (TMO) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
TMO to Report Q2 Earnings: Analytical Instruments Segment in Focus
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
Thermo Fisher eyes second-quarter 2025 growth with new tech launches in Analytical Instruments and Life-Science Solutions segments.
Read More
Analysts Estimate Thermo Fisher Scientific (TMO) to Report a Decline in Earnings: What to Look Out for
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Negative
Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Thermo Fisher acquires Sanofi's New Jersey manufacturing site
Published: July 16, 2025 by: Reuters
Sentiment: Positive
Thermo Fisher said on Wednesday it will buy Sanofi's manufacturing site in Ridgefield, New Jersey, to produce critical medicines for the French drugmaker.
Read More
Thermo Fisher Scientific Introduces the Oncomine Comprehensive Assay Plus on the Ion Torrent Genexus System to Help Advance the Future of Precision Medicine
Published: July 14, 2025 by: Business Wire
Sentiment: Neutral
CARLSBAD, Calif.--(BUSINESS WIRE)--Today, Thermo Fisher Scientific announced that the Oncomine™ Comprehensive Assay Plus* is now available on the Ion Torrent™ Genexus™ System* helping accelerate precision oncology research. The Oncomine Comprehensive Assay Plus detects a broad range of genomic alterations in 517 genes and will now be able to deliver comprehensive genomic profiling (CGP) results as soon as the next day, enabled by Ion Torrent technology and easy, automated workflows. CGP facilit.
Read More
Should You Continue to Hold Thermo Fisher Stock in Your Portfolio Now?
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Negative
TMO's growth via acquisitions and product launches is strong, but macro pressures and FX headwinds cloud the outlook.
Read More
4 Of The Hottest Great American SWANs For The 4th Of July
Published: July 04, 2025 by: Seeking Alpha
Sentiment: Positive
I highlight four American SWAN stocks - Realty Income, Alphabet, Globe Life, and Thermo Fisher Scientific - offering stress-free, blue-chip investment opportunities. Each company boasts strong management, robust balance sheets, consistent earnings, and attractive valuations, trading 18-24% below my fair value estimates. These stocks offer a blended 1.8% yield, low payout ratios, and A or AA credit ratings, supporting reliable dividend growth and low long-term risk.
Read More
Thermo Fisher Scientific Awarded $94.5 Million U.S. Government Contract to Supply the Navy with Advanced Radiation Detection Systems
Published: June 23, 2025 by: Business Wire
Sentiment: Neutral
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced that it has been awarded a five-year, $94.5 million contract by the U.S. Department of Defense (DoD) to supply the Navy with a next-generation dosimetry system alongside updated radiation health and database management software. The U.S. Navy operates the world's most technologically advanced naval fleet and is the largest defense user of dosimetry systems globally. With this award, T.
Read More
Report: Biotech Research Firm Thermo Fisher Considers Selling Diagnostics Business
Published: June 13, 2025 by: PYMNTS
Sentiment: Negative
Biotechnology research firm Thermo Fisher Scientific is reportedly looking to sell part of its diagnostics business amid industrywide concerns about federal cutbacks in spending on research.
Read More
Thermo Fisher Stock Hurt by Macroeconomic Woes, Tough Competition
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Neutral
TMO grapples with macro pressures, rising expenses and fierce competition, but bets on acquisitions to fuel recovery.
Read More
TMO Launches Next-Generation Mass Spectrometers: Stock to Gain?
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Neutral
Thermo Fisher debuts two advanced MSs, Orbitrap Astral Zoom and Orbitrap Excedion Pro, to accelerate precision medicine and drug discovery breakthroughs.
Read More
Thermo Fisher Scientific Unveils Next-generation Mass Spectrometers at ASMS 2025 to Revolutionize Biopharma Applications and Omics Research
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the launch of the Thermo Scientific™ Orbitrap™ Astral™ Zoom mass spectrometer (MS) and the Thermo Scientific™ Orbitrap™ Excedion™ Pro mass spectrometer (MS) to help push the boundaries of scientific discovery. Delivering unrivaled analytical performance and speed, the instruments are designed to uncover complex biological processes that could lead to advancements in p.
Read More
Thermo Fisher: With A 30% Price Drop, Trump Legislation, And High Capex, Is It Undervalued?
Published: June 02, 2025 by: Seeking Alpha
Sentiment: Positive
The neutral DCF model implemented in this article suggests that Thermo Fisher is undervalued by 29.24%. Thermo Fisher has invested, on average, 16.51% of its revenues in capex between 2019 and 2024. Due to the significant investment in capex, Thermo Fisher's revenues have increased at a 12.95% CAGR between 2019 and 2024.
Read More
Thermo Fisher Is Strengthening Its Long-Term Advantage
Published: June 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Thermo Fisher's 2025 headwinds from tariffs and US research funding cuts are real but temporary, not reflective of structural weakness in its fundamentals. The company is mitigating trade impacts by investing $2B in US manufacturing, leveraging diversification and innovation, and expects headwinds to peak this year. Biopharma growth, strategic acquisitions, and rapid product innovation position TMO for long-term outperformance versus less diversified peers.
Read More
TMO Stock Set to Gain From the Launch of New Narcotic Analyzers
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Thermo Fisher launches new TruNarc analyzers to help law enforcement quickly detect 1,200+ substances, boosting field safety and drug interdiction efforts.
Read More
Why Is Thermo Fisher (TMO) Down 6.1% Since Last Earnings Report?
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Negative
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock?
Read More
Thermo Fisher Scientific Introduces Next Generation TruNarc Handheld Narcotics Analyzers to Support Public Safety
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today introduced the Thermo Scientific™ TruNarc™ Delta and Tau Handheld Narcotics Analyzers* to help communities combat known and emerging narcotics and illicit substances. With touchless technology and an expanded chemical library, the user-friendly devices empower frontline law enforcement officials to identify more than 1,200 substances in the field, including stimulants, depressants, hallucinogen.
Read More
10 Undervalued Dividend Growth Stocks: May 2025
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Positive
I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the top ten stocks for consideration. I use two valuation screens, one based on my fair value estimate, and another comparing each stock's forward dividend yield with its 5-year average dividend yield. To rank stocks, I do a quality assessment and sort candidates by quality scores, breaking ties with additional metrics.
Read More
3 Of The Cheapest High-Quality Stocks Money Can Buy
Published: April 30, 2025 by: Seeking Alpha
Sentiment: Positive
Geopolitical risks and economic uncertainty have battered markets, but I view this turmoil as an opportunity to buy high-quality, undervalued stocks. Despite volatility and weak earnings trends, I'm focused on companies trading well below fair value, with strong fundamentals and long-term growth potential. In this article, I highlight three dirt-cheap stocks across different industries that I believe can deliver significant returns in the years ahead.
Read More
Thermo Fisher's Q1 Earnings Top Estimates, Revenues Beat, Stock Up
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Positive
TMO continues to advance its growth strategy and trusted partner status with customers in the first quarter of 2025.
Read More
About Thermo Fisher Scientific Inc. (TMO)
- IPO Date 1980-03-17
- Website https://www.thermofisher.com
- Industry Medical - Diagnostics & Research
- CEO Marc N. Casper
- Employees 125000